A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Autologous muscle-derived stem cell therapy Cook MyoSite (Primary)
- Indications Stress incontinence; Urinary incontinence
- Focus Therapeutic Use
- Acronyms IND2
- Sponsors Cook MyoSite
- 10 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Apr 2016 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019 as reported by ClinicalTrials.gov record.
- 07 Apr 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018 as reported by ClinicalTrials.gov record.